Oral antiviral therapy for COVID-19? update to our management guidelines - Jan 26, 2022

Oral antiviral therapy (nirmatrelvir/ritonavir or Paxlovid) is now available in Quebec for selected patients who are at high risk of progression to severe disease AND identified early (<5days) after onset of symptoms.. Beware drug-drug interactions and limited supply - our latest guidelines offer an approach for outpatient management of COVID-19 for vulnerable high-risk patients. Enjoy!

Recent Posts

See All

Update in COVID guidelines

The ASP committee updated the COVID guidelines. You will find the following change: -Removal of the pre-exposure prophylaxis guidelines since monoclonal antibodies are no longer easly available. -Clar

Correction in Antifungal prophylaxis for high-risk (immunocompromised)

Correction made for Heart transplant and Lung transplant recipients: both anti-mold AND anti-PJP prophylaxis recommended.

NEW UPDATE: *Change in process for outpatient COVID-19 management*

To MUHC users: Please note that as of Dec 5, 2022, requests for outpatient antiviral management of COVID-19 for HIGH RISK patients should be directed to the ID-AMB (formerly MicroB/Lachine) service ra